Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2KRAS p, G12c Mutated /Advanced Metastatic NSCLC 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Prednisone 9Pemetrexed 9Epoetin Alfa 9venetoclax 8atezolizumab 8Fentanyl 8Drug Therapy 8Doxorubicin 8Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × sotorasib × Clear all
NCT05920356 2026-06-04

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Amgen

Phase 3 Recruiting
750 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06252649 2026-04-24

CodeBreaK 301

Amgen

Phase 3 Recruiting
450 enrolled
Gastrointestinal

Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡